Oncology Target Series: Triple-Negative Breast Cancer (TNBC)

Navigate the Complex Landscape of TNBC Targets

Report
TNBC is an aggressive breast cancer subtype with poor prognosis, characterized by an absence of ER, PR and HER2 expression. Its resistance to traditional hormonal or anti-HER2 therapies highlights the urgent need for identifying novel targets to improve outcomes
What You'll Gain:
  • Target Class Analysis: Understand the distribution of TNBC targets across different target classes.
  • Findings from Animal Studies: Learn about targets studied in animal models, including mice.
  • Targets in Clinical Studies: Stay ahead of the curve with a comprehensive overview of TNBC targets being investigated in clinical trials.
  • Emerging Targets: Stay at the forefront of innovation and target insights in the last 5 years.

Request your copy of
Oncology Target Series: Triple-Negative Breast Cancer (TNBC)

Fill out the form below to access the full report.

‌